Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) fell 2.6% on Thursday . The stock traded as low as $11.02 and last traded at $11.03, with a volume of 97,039 shares trading hands. The stock had previously closed at $11.33.

Several research firms recently weighed in on MNTA. Goldman Sachs Group Inc. began coverage on Momenta Pharmaceuticals in a research note on Monday, June 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Brean Capital reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 27th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective (down from $21.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.40.

The company’s 50-day moving average is $11.14 and its 200-day moving average is $10.80. The stock’s market capitalization is $779.91 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. During the same quarter in the previous year, the firm posted ($0.40) EPS. The business earned $19.90 million during the quarter, compared to analysts’ expectations of $28.12 million. Momenta Pharmaceuticals’s revenue for the quarter was up 132.5% on a year-over-year basis. Analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.32) EPS for the current fiscal year.

In related news, VP John E. Bishop sold 2,843 shares of the business’s stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $9.57, for a total transaction of $27,207.51. Following the sale, the vice president now directly owns 160,880 shares in the company, valued at approximately $1,539,621.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 5,880 shares of the business’s stock in a transaction on Friday, May 20th. The shares were sold at an average price of $10.18, for a total value of $59,858.40. Following the sale, the president now owns 349,521 shares in the company, valued at $3,558,123.78. The disclosure for this sale can be found here.

Several hedge funds recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its stake in Momenta Pharmaceuticals by 350.4% in the fourth quarter. Wells Fargo & Company MN now owns 110,300 shares of the biotechnology company’s stock worth $1,637,000 after buying an additional 85,813 shares during the last quarter. Stevens Capital Management LP bought a new stake in Momenta Pharmaceuticals during the fourth quarter worth about $1,109,000. Principal Financial Group Inc. raised its stake in Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock worth $6,279,000 after buying an additional 18,504 shares during the last quarter. California State Teachers Retirement System raised its stake in Momenta Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,170 shares of the biotechnology company’s stock worth $1,679,000 after buying an additional 1,801 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 66,130 shares during the last quarter.

Momenta Pharmaceuticals, Inc (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company’s product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.